Selected research
Industry Research
Deferoxamine Industry Research Report 2026
Market perspective
The global Deferoxamine market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Deferoxamine is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Deferoxamine is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Deferoxamine is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Deferoxamine include APP Pharmaceuticals, Gland Pharma, Hospira, Novartis Pharmaceuticals, Watson Laboratories, West-Ward Pharms, Fresenius Kabi and Novartis, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Deferoxamine market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Deferoxamine Market by Company
APP Pharmaceuticals
Gland Pharma
Hospira
Novartis Pharmaceuticals
Watson Laboratories
West-Ward Pharms
Fresenius Kabi
Novartis
Deferoxamine Segment by Type
Injection for Solution
Powder for Solution
Lyophilized for Solution
Deferoxamine Segment by Application
Acute Iron Intoxication
Aluminum Overload
Chronic Aluminum Overload
Chronic Iron Overload
Deferoxamine Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Deferoxamine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Deferoxamine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Deferoxamine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Deferoxamine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Deferoxamine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Deferoxamine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Injection for Solution
- Powder for Solution
- Lyophilized for Solution
Applications
- Acute Iron Intoxication
- Aluminum Overload
- Chronic Aluminum Overload
- Chronic Iron Overload
Companies covered
- APP Pharmaceuticals
- Gland Pharma
- Hospira
- Novartis Pharmaceuticals
- Watson Laboratories
- West-Ward Pharms
- Fresenius Kabi
- Novartis
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Deferoxamine Market Size (2021-2032)
- 2.2.2 Global Deferoxamine Sales (2021-2032)
- 2.2.3 Global Deferoxamine Market Average Price (2021-2032)
- 2.3 Deferoxamine by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Injection for Solution
- 2.3.3 Powder for Solution
- 2.3.4 Lyophilized for Solution
- 2.4 Deferoxamine by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Acute Iron Intoxication
- 2.4.3 Aluminum Overload
- 2.4.4 Chronic Aluminum Overload
- 2.4.5 Chronic Iron Overload
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Deferoxamine Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Deferoxamine Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Deferoxamine Revenue of Manufacturers (2021-2026)
- 3.4 Global Deferoxamine Average Price by Manufacturers (2021-2026)
- 3.5 Global Deferoxamine Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Deferoxamine, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Deferoxamine, Product Type & Application
- 3.8 Global Manufacturers of Deferoxamine, Established Date
- 3.9 Global Deferoxamine Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 APP Pharmaceuticals
- 4.1.1 APP Pharmaceuticals Company Information
- 4.1.2 APP Pharmaceuticals Business Overview
- 4.1.3 APP Pharmaceuticals Deferoxamine Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 APP Pharmaceuticals Deferoxamine Product Portfolio
- 4.1.5 APP Pharmaceuticals Recent Developments
- 4.2 Gland Pharma
- 4.2.1 Gland Pharma Company Information
- 4.2.2 Gland Pharma Business Overview
- 4.2.3 Gland Pharma Deferoxamine Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Gland Pharma Deferoxamine Product Portfolio
- 4.2.5 Gland Pharma Recent Developments
- 4.3 Hospira
- 4.3.1 Hospira Company Information
- 4.3.2 Hospira Business Overview
- 4.3.3 Hospira Deferoxamine Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Hospira Deferoxamine Product Portfolio
- 4.3.5 Hospira Recent Developments
- 4.4 Novartis Pharmaceuticals
- 4.4.1 Novartis Pharmaceuticals Company Information
- 4.4.2 Novartis Pharmaceuticals Business Overview
- 4.4.3 Novartis Pharmaceuticals Deferoxamine Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Novartis Pharmaceuticals Deferoxamine Product Portfolio
- 4.4.5 Novartis Pharmaceuticals Recent Developments
- 4.5 Watson Laboratories
- 4.5.1 Watson Laboratories Company Information
- 4.5.2 Watson Laboratories Business Overview
- 4.5.3 Watson Laboratories Deferoxamine Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Watson Laboratories Deferoxamine Product Portfolio
- 4.5.5 Watson Laboratories Recent Developments
- 4.6 West-Ward Pharms
- 4.6.1 West-Ward Pharms Company Information
- 4.6.2 West-Ward Pharms Business Overview
- 4.6.3 West-Ward Pharms Deferoxamine Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 West-Ward Pharms Deferoxamine Product Portfolio
- 4.6.5 West-Ward Pharms Recent Developments
- 4.7 Fresenius Kabi
- 4.7.1 Fresenius Kabi Company Information
- 4.7.2 Fresenius Kabi Business Overview
- 4.7.3 Fresenius Kabi Deferoxamine Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Fresenius Kabi Deferoxamine Product Portfolio
- 4.7.5 Fresenius Kabi Recent Developments
- 4.8 Novartis
- 4.8.1 Novartis Company Information
- 4.8.2 Novartis Business Overview
- 4.8.3 Novartis Deferoxamine Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Novartis Deferoxamine Product Portfolio
- 4.8.5 Novartis Recent Developments
5 Global Deferoxamine Market Scenario by Region
- 5.1 Global Deferoxamine Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Deferoxamine Sales by Region: 2021-2032
- 5.2.1 Global Deferoxamine Sales by Region: 2021-2026
- 5.2.2 Global Deferoxamine Sales by Region: 2027-2032
- 5.3 Global Deferoxamine Revenue by Region: 2021-2032
- 5.3.1 Global Deferoxamine Revenue by Region: 2021-2026
- 5.3.2 Global Deferoxamine Revenue by Region: 2027-2032
- 5.4 North America Deferoxamine Market Facts & Figures by Country
- 5.4.1 North America Deferoxamine Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Deferoxamine Sales by Country (2021-2032)
- 5.4.3 North America Deferoxamine Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Deferoxamine Market Facts & Figures by Country
- 5.5.1 Europe Deferoxamine Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Deferoxamine Sales by Country (2021-2032)
- 5.5.3 Europe Deferoxamine Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Deferoxamine Market Facts & Figures by Country
- 5.6.1 Asia Pacific Deferoxamine Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Deferoxamine Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Deferoxamine Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Deferoxamine Market Facts & Figures by Country
- 5.7.1 South America Deferoxamine Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Deferoxamine Sales by Country (2021-2032)
- 5.7.3 South America Deferoxamine Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Deferoxamine Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Deferoxamine Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Deferoxamine Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Deferoxamine Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Deferoxamine Sales by Type (2021-2032)
- 6.1.1 Global Deferoxamine Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Deferoxamine Sales Market Share by Type (2021-2032)
- 6.2 Global Deferoxamine Revenue by Type (2021-2032)
- 6.2.1 Global Deferoxamine Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Deferoxamine Revenue Market Share by Type (2021-2032)
- 6.3 Global Deferoxamine Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Deferoxamine Sales by Application (2021-2032)
- 7.1.1 Global Deferoxamine Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Deferoxamine Sales Market Share by Application (2021-2032)
- 7.2 Global Deferoxamine Revenue by Application (2021-2032)
- 7.2.1 Global Deferoxamine Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Deferoxamine Revenue Market Share by Application (2021-2032)
- 7.3 Global Deferoxamine Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Deferoxamine Value Chain Analysis
- 8.1.1 Deferoxamine Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Deferoxamine Production Mode & Process
- 8.2 Deferoxamine Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Deferoxamine Distributors
- 8.2.3 Deferoxamine Customers
9 Global Deferoxamine Analyzing Market Dynamics
- 9.1 Deferoxamine Industry Trends
- 9.2 Deferoxamine Industry Drivers
- 9.3 Deferoxamine Industry Opportunities and Challenges
- 9.4 Deferoxamine Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst